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Objective: Primary platinum-resistant epithelial ovarian cancer (EOC) is an area of unmet
medical need. There is limited evidence from small studies that platinum-based combinations
can overcome ‘‘resistance’’ in a proportion of patients.We investigated the efficacy and toxicity
of platinum-based combination chemotherapy in the platinum-resistant and platinum-
refractory setting.
Methods: Epirubicin, cisplatin, and capecitabine (ECX) combination chemotherapy was
used at our institution for the treatment of relapsed EOC. From the institutional database, we
identified all patients with primary platinum-refractory or platinum-resistant relapse treated
with ECX as second-line therapy between 2001 and 2012. We extracted demographic,
clinical, treatment, and toxicity data and outcomes. We used logistic and Cox regression
models to identify predictors of response and survival respectively.
Results: Thirty-four 34 patients (8 refractory, 26 resistant) were treated with ECX. Response
Evaluation Criteria In Solid Tumors (RECIST) response rate was 45%, median progression-
free survival (PFS) was 6.4 months, and overall survival (OS) was 10.6 months. Platinum-
resistant patients had better outcomes than did platinum-refractory patients (response
rate, 54% vs 0%, P = 0.047; PFS 7.2 vs 1.8 months, P G 0.0001; OS 14.4 vs 3 months, P G
0.001). In regression models, time to progression after first-line treatment and platinum-
refractory status were the strongest predictors of response and PFS or OS, respectively. Pa-
tients with time to progression after first-line treatment longer than 3 months showed PFS and
OS of 7.9 and 14.7 months, respectively. Toxicity was manageable, with only 13% of cycles
administered at reduced doses.
Conclusions: Epirubicin, cisplatin, and capecitabine seems to be active in platinum-
resistant relapsed EOC with manageable toxicity. Further prospective investigation of
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platinum-anthracycline combinations is warranted in patients who relapse 3 to 6 months
after first-line platinum-taxane treatment.
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Epithelial ovarian cancer (EOC) is a significant cause ofmorbidity and the commonest cause of death from gyne-
cologic cancer.1 For most patients presenting with stage III-IV
disease, first-line treatment consists of debulking surgery and
chemotherapy with a platinum taxane doublet, most com-
monly carboplatin and paclitaxel.
Despite frequent complete responses (CRs) to first-line
treatment, relapse occurs in up to 85% of patients with stage
III-IV disease, with a median time to relapse of 18 months.2
Approximately a third of these relapses occur within 6 months
of first-line treatment,3 and the disease is then considered pri-
mary platinum resistant or refractory. Single-agent treatment
with a nonplatinum drug is the preferred treatment option in
this setting4,5; commonly used drugs are pegylated liposomal
doxorubicin (PLD), topotecan, and, more recently, weekly
paclitaxel. However, outcomes are poor, with response rates
(RRs) ranging from 6% to 12% for PLD and topotecan6,7 and
27% to 35% for weekly paclitaxel.8,9 Median progression-free
survival (PFS) and overall survival (OS) typically range from 3
to 6 months and from 10 to 13 months, respectively, with some
improvement in the latter in more recent studies, particularly
those incorporating weekly paclitaxel.6Y10
However, platinum resistance is generally not absolute.
Response rates of 29% to 39% have been reported in small
studies of platinum-based regimens such as cisplatin etoposide,
cisplatin gemcitabine, or oxaliplatin 5-fluorouracil in platinum-
resistant patients, suggesting that combination cisplatin or
oxaliplatin containing chemotherapy can overcome ‘‘platinum
resistance’’ in some patients.11Y13 Consequently, efforts are
being made to try new platinum-based combinations both in
the platinum sensitive and the ‘‘platinum-resistant’’ setting.
Previous work by Ahmed et al14 demonstrated an RR of 41%
for recurrent ovarian cancer, relapsing within 12 months of
prior platinum treatment, using the 3-drug combination of
epirubicin, cisplatin, and continuous infusional 5-fluoruracil.
Because the delivery of infusional 5-fluorouracil requires an
indwelling central venous catheter, the same group investi-
gated the combination of epirubicin, carboplatin, and the oral
fluoropyrimidine capecitabine (ECarboX) in patients with
disease relapsing 6 months or more after prior platinum
treatment.15 Eleven (61%) of 18 patients demonstrated either
complete or partial radiologic response, implying consider-
able activity of this combination. However, hematologic tox-
icity was significant, necessitating frequent dose reductions
and interruptions.
These encouraging reports of preliminary activity have
led to the frequent use of a modified ECarboX regimen in our
institution for fit patients with platinum-refractory or resistant
relapse. Specifically, we resubstituted cisplatin for carboplatin
to ameliorate haematologic toxicity, leading to a regimen of
epirubicin, cisplatin, and capecitabine (ECX). We report here
our institutional experience with this regimen, over more
than a decade, in patients with first platinum-refractory or
resistant relapse.
METHODS
This is a retrospective single-center case series of pa-
tients with ovarian cancer receiving ECX as first relapse
therapy at Addenbrooke’s Hospital, Cambridge, UK, between
January 2001 and September 2012. To be included in the series,
patients required histologically confirmed EOCwith platinum-
refractory or platinum-resistant relapse after first-line treat-
ment with platinum-based chemotherapy. Platinum-refractory
relapse was defined as radiologic progression on treatment or
within 1month of the final cycle of first-line platinum treatment
(day 1). Platinum-resistant relapsewas defined similarly, except
that time to progression was between 1 and 6 months after first-
line treatment. Patients were excluded if they had platinum-
sensitive disease (relapse 96 months from prior platinum
treatment), nonepithelial ovarian malignancy, had received
more than 1 line of previous chemotherapy in the relapse
setting, or received ECX after suboptimal debulking surgery
without documented disease progression.
Treatment Administration
Epirubicin was administered as a bolus dose of 50 mg/m2
on day 1, followed by cisplatin 60 mg/m2 as a 3-hour infusion
with conventional preinfusion and postinfusion hydration.
Capecitabine was administered orally at a dose of 650 mg/m2
twice a day for 14 days, starting on the evening of day 1.
Standard antiemetic prophylaxis consisted of ondansentron and
dexamethasone, with aprepitant added in selected patients in
more recent years. Cycles were repeated every 3 weeks for a
maximumof6 cycles of treatment.Thedecision toproceedwith
each subsequent cycle of treatment rested with the reviewing
clinician, although, generally, a neutrophil count greater than
1.0 109/L and a platelet count greater than 100 109/L were
required.Growth factor supportwas not routinely administered.
Data Collection
Demographic information, histologic details, details of
first-line treatment, and any previous surgery were extracted
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from the clinical records.Epirubicin, cisplatin, and capecitabine
administration details, including actual administered doses,
dose reductions, and delays, were extracted from the pharmacy
database and, since 2011, from the computerized chemotherapy
prescription platform (Aria). Nonhematologic toxicity grading
was extracted from prospectively recorded toxicity charts in the
clinical records. Hematologic and biochemical toxicities were
extracted from the hospital electronic database and graded
according to National Cancer Institute-Common Toxicity
Criteria Version 4.0.
Assessment of Response
Patients were assessed clinically and with serum cancer
antigen 125 (CA-125) measurements before each cycle of
treatment. Disease burden was measured with computed to-
mography at baseline, approximately every 9 weeks while
receiving ECX and every 12 weeks after completion of che-
motherapy. All scans were retrospectively evaluated according
to Response Evaluation Criteria In Solid Tumors (RECIST)
1.1 by consultant radiologists specializing in gynecologic cancer,
and overall response was reported. Repeat imaging was not
carried out to confirm response.
Outcome Measures
Best radiologic responses and CA-125 responses were
recorded according to both RECIST and GCIG criteria, re-
spectively.16,17 Clinical benefit rate was defined as the pro-
portion of patients achieving RECIST response or stable
disease (SD) for at least 8 weeks. Progression-free survival
was calculated as the interval from the first day of ECX
administration to unequivocal clinical or radiologic (but not
CA-125) disease progression or death from any cause,
whichever occurred first. Overall survival was calculated
as the interval from the first day of ECX administration to
death. All patients included in this series have died, and
therefore, there are no censored observations. Feasibility and
tolerability of the regimen were recorded as manifested by
dose reductions, treatment delays, and grade 3/4 toxicities.
Statistics
Descriptive statistics are presented as mean T SD or as
median with interquartile range (IQR), as appropriate. Pro-
portions were compared with the Fisher exact test. Survival
curves were constructed using the Kaplan-Meier method.
Univariate and multivariate logistic regressions were per-
formed to identify modifiers of response. Survival curves were
compared with the log-rank test, and Cox regression was
performed to identify modifiers of PFS and OS. Variables en-
tered in the logistic and Cox regressions were age (in years),
histologic subtype (clear cell vs others), International Federa-
tion of Gynecology and Obstetrics stage (IV vs III), first-line
treatment (carboplatin paclitaxel vs carboplatin), resistance
type (resistant vs refractory), and time to progression after
first-line treatment (TTP1; in days as a continuous variable).
Variables with P G 0.2 were entered in multivariate models that
were constructed using backward selection. All analyses were
performed using GraphPad Prism v6 (San Diego, CA) and
MedCalc v13.2.2.0 (Ostend, Belgium). P G 0.05 indicates
statistical significance.
RESULTS
Patient Characteristics
Thirty-four patients commenced treatment with second
line ECX between June 2004 and February 2011. Patient char-
acteristics are summarized in Table 1. Median age was 58 years
(range, 35Y72 years), and all patients presented with stage III or
IV disease. The predominant histology was high-grade serous
EOC (68% of cases). Twenty-one (62%) patients underwent
optimal debulking surgery (G1 cm of residual), and 11 (32%)
had nomacroscopic residual at the end of their operation. Eight
(24%) patients progressed on or within 1 month of first-line
chemotherapy and were considered platinum refractory, and
6 (75%) of these 8 patients had clear cell histology. All patients
had progressed within 6 months after first-line treatment and
were therefore considered platinum resistant. Median TTP1
was 115 days (IQR, 64.5Y161.3), and median treatment-free
interval was 136.5 days (IQR, 78.75Y183.8).
Treatment Administration
The median number of ECX cycles administered per
patient was 6, for a total of 168 cycles. The proportion of
cycles with at least 90% of the planned dose administered
was 93% for epirubicin, 79% for cisplatin, and 81% for
TABLE 1. Patient characteristics
Age, median (range), y 58 (35Y72)
Stage
III 23 (68)
IV 11 (32)
Histology
Serous* 25 (74)
Clear cell 6 (18)
Endometrioid 2 (6)
Not classified 1 (3)
Attempted surgery 31 (91)
Interval debulking 23 (68)
Surgical outcome
Optimal debulking 21 (68)
Suboptimal debulking 10 (32)
Performance status
0 10 (32)
1 13 (38)
2 2 (6)
Missing 9 (26)
First-line chemotherapy
Carboplatin + paclitaxel 31 (91)
Carboplatin 3 (9)
Platinum resistant 26 (76)
Platinum refractory 8 (24)
Values are presented as no. (%), unless otherwise indicated.
*One patient had areas of clear cell differentiation.
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capecitabine. Median dose delivered was 50 and 60 mg/m2 for
epirubicin and cisplatin, respectively. Themediandelivereddose
of capecitabine was 650 mg/m2 twice a day for 14 of 21 days
per cycle. It should be noted that the first 7 patients were
started on continuous capecitabine; all required a change
to a 2-week on/1-week off schedule due to toxicity. Overall,
19 (56%) of patients completed 6 cycles of ECX. The most
common reason for stopping early was disease progression,
occurring in 10 (29%) patients.
Twelve (35%) patients had a dose reduction for at least 1
drug in the regimen,most commonly capecitabine. Capecitabine
wasdiscontinued in3 cases (2due to chest pain and1 for diarrhea
and palpitations) and cisplatin in 1 (due to ototoxicity), with no
other modifications to the rest of the regimen. In total, 22 (13%)
cycles were delayed, with neutropenia being the predominant
reason (Table S1, available online as Supplemental Digital
Content at http://links.lww.com/IGC/A286).
Efficacy
Twenty-nine patients were evaluable by RECIST criteria
(Table 2). For 5 patients, treated in the earlier years of this series,
scans were not available for review. None of these patients had
documented early clinical progression before the first assess-
ment performed after approximately 9 weeks of treatment. The
best radiologic responses were CR in 2 (7%) patients, partial
response (PR) in 11 (38%), SD in 9 (31%), and progressive
disease (PD) in 7 (24%), for a best overall RR (ORR) of 45%.
Responses tended to occur early, with 8 of the 13 documented
at the first interim scan. There were no responses in the plati-
num refractory group. Two of the 5 assessable refractory pa-
tients had SD and 3 had PD. The ORR was significantly higher
in platinum-resistant compared with platinum-refractory pa-
tients (P = 0.047). In univariate logistic regression (Table 3),
only TTP1 was a significant predictor of CR/PR (P = 0.015),
and therefore, multivariate regression was not performed. It
should be noted that because there were no responses in pa-
tients with platinum-refractory or clear cell disease, logistic
regression results for these parameters were nonestimable.
The clinical benefit rate was 83% in platinum-resistant
and 40% in platinum-refractory patients (P = 0.07). In uni-
variate logistic regression (Table 3), platinum-refractory pa-
tients were less likely to exhibit clinical benefit (odds ratio
[OR], 0.13; 95% confidence interval [CI], 0.02Y1.07; P =
0.058), as were patients with shorter TTP1 (P = 0.025). Time
to progression after first-line treatment was the only variable
retained as significant in a multivariate model (P = 0.03).
Twenty-six patients were evaluable for CA-125 response
evaluation, with 18 (69%) achieving a response by GCIG
criteria (7 CR, 11 PR). Significantly more patients with
platinum-refractory compared with resistant disease showed
CA-125 progression as their best marker response (4/6 vs
2/20, P = 0.013). Of note, 5 patients were CA-125 but not
RECISTevaluable; 2 (40%) showed a CA-125 PR and 3 (60%)
showed PD.
Median PFS for the 34 patients was 6.4 months. It was
7.2 and 1.8 months for platinum-resistant and platinum-
refractory patients, respectively (P G 0.0001; Fig. 1). Similarly,
median OS was 10.6 months. Patients with platinum-refractory
disease showed a very short median OS of 3 months compared
with 14.4 months for platinum-resistant patients (P G 0.0001;
Fig. S1, available online as Supplemental Digital Content at
http://links.lww.com/IGC/A286).
In univariate Cox regression, platinum-refractory status
increased the risk of a PFS event by a factor of 10 (hazard ratio
[HR], 10.71; P G 0.0001). Clear cell histologic subtype (P =
0.0006) and shorter TTP1 (P e 0.0001) also predicted shorter
PFS (Table 4). In a multivariate model, platinum-refractory
TABLE 2. Best response to ECX by RECIST criteria
RECIST Response Frequency %
CR 2 7
PR 11 38
SD 9 31
PD 7 24
TABLE 3. Logistic regression of response variables
Variable
Response
(CR/PR) vs None (SD/PD)
Clinical Benefit
(CR/PR/SD) vs None (PD)
Coefficient OR (95% CI) P Coefficient OR (95% CI) P
Age j0.0123 0.99 (0.91Y1.07) 0.763 0.0155 1.02 (0.93Y1.11) 0.738
Histologic subtype
(other vs clear cell)
Nonestimable 0.5108 1.67 (0.13Y21.73) 0.697
Stage (IV vs III) 0.9445 2.57 (0.53Y12.38) 0.239 1.424 4.154 (0.42Y40.67) 0.221
Surgery (no
surgery/suboptimal
debulking vs optimal)
j0.5596 0.57 (0.13Y2.66) 0.476 j0.2719 0.76 (0.13Y4.3) 0.758
Resistance type
(refractory vs resistant)
Non-estimable j2.0149 0.13 (0.02Y1.07) 0.058
TTP1 0.0245 1.02 (1.00Y1.05) 0.015 0.0191 1.02 (1.00Y1.04) 0.025
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status (P = 0.0025) and TTP1 (P = 0.021) were retained as
independent predictors of PFS. Platinum-refractory status (HR,
8.05; P = 0.0001), clear cell histology (HR, 12.5; P = 0.0002),
shorter TTP1 (P = 0.0001), shorter PFS (P = 0.0001), and
nonresponse to ECX (P = 0.007) were significant predictors
of shorter survival in univariate analysis (Table 4). When all
5 variables were entered in a multivariate model, platinum-
refractory status was the single most significant predictor
of shorter OS (HR, 6.85; 95% CI, 1.95Y23.99; P = 0.003).
Complete response/PR to ECX was also retained in the
model as a predictorof longerOS (HR,0.42;95%CI, 0.18Y0.98;
P = 0.046).
In a further analysis, we looked at the outcomes in patients
with TTP1 9 3 months. Median PFS and OS in the 23 patients
with TTP1 9 3 months were 7.9 and 14.7 months compared
with 1.8 and3.2months in the 11 patientswith TTP1G 3months
(P = 0.006 and P G 0.0001, respectively; Fig. 2). This re-
mained the case when patients with clear cell histology
were excluded (PFS 1.8 vs 7.5 months, P G 0.0001: OS 6.8 vs
14.7 months, P = 0.0002). Interestingly, patients with CR/PR
at first interim assessment had significantly prolonged sur-
vival compared with patients with SD (median OS 23.2 vs
10.2 months, respectively; P = 0.02); survival of the latter was
very similar to that of patients with PD at first assessment
(median, 8.3 months; P = 0.88).
Toxicity
Hematologic toxicity was common, with 17 (50%) of
patients experiencing grade 3 or 4 neutropenia (Table S2,
available online as Supplemental Digital Content at
http://links.lww.com/IGC/A286) of whom 6 (18%) had G4
neutropenia. One (3%) patient experienced grade 4 throm-
bocytopenia, without bleeding. Twenty (59%) patients ex-
perienced grade 2 anemiawith no recorded grade 3/4 toxicity.
Growth factor support was infrequent, with only 1 patient
receiving secondary granulocyte colony-stimulating factor
prophylaxis for 2 cycles. Of the nonhematologic toxicities
(Table S3, available online as Supplemental Digital Content at
http://links.lww.com/IGC/A286), nausea, vomiting, and fatigue
were most common. Ten (30%) patients) patients had grade 3
or 4 vomiting; 13 (38%) and 6 (18%) patients had grade 3
nausea and fatigue, respectively. There were a total of 17 hos-
pital admissions, affecting 13 patients during treatment. One
patient with known generalized atherosclerotic disease had
2 hospital admissions related to lower limb ischaemia, judged
unrelated to the chemotherapy, and eventually underwent
amputation. There were 9 infection-related admissions, with
neutropenia documented in 4 patients, to give an overall 12%
rate for patients experiencing febrile neutropenia. The remain-
ing admissions were predominantly for symptom control,
FIGURE 1. PFS in platinum-refractory and
platinum-resistant patients treated with ECX.
TABLE 4. Univariate analysis of PFS and OS predictors
Variable
PFS OS
Coefficient HR (95% CI) P Coefficient HR (95% CI) P
Age j0.0138 0.99 (0.96Y1.02) 0.397 0.0081 1.01( 0.97Y1.05) 0.6787
Histologic subtype
(other vs clear cell)
j1.9791 0.14 (0.05Y0.42) 0.0006 j2.5240 0.08 (0.02Y0.3) 0.0002
Stage (IV vs III) j0.3538 0.70 (0.33Y1.48) 0.3556 j0.3201 0.73 (0.35Y1.52) 0.4001
Surgery (no surgery/suboptimal
debulking vs optimal)
0.1036 1.11 (0.55Y2.23) 0.7726 0.1272 1.14 (0.56Y2.32) 0.728
First line treatment
(carboplatin vs carboplatin
paclitaxel)
0.5047 1.66 (0.5Y5.5) 0.4124 0.116 1.12 (0.34Y3.71) 0.85
Resistance type
(refractory vs resistant)
2.3716 10.71 (3.55Y32.32) G0.0001 2.0853 8.05 (2.78Y23.26) 0.0001
TTP1 j0.0158 0.984 (0.977Y0.992) G0.0001 j0.0135 0.99 (0.98Y0.993) 0.0001
Response (CR/PR vs SD/PD) j0.3682 0.69 (0.32Y1.48) 0.3466 j1.0796 0.34 (0.16Y0.74) 0.007
PFS j0.0092 0.991 (0.986Y0.996) 0.0001
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although 2 patients were admitted with chest pain attributed
to capecitabine.
DISCUSSION
Platinum-refractory or resistant ovarian cancer represents
an area of unmet medical need. Despite intensive research ef-
forts over the last 2 decades, standard treatment options re-
main limited to single-agent treatment with nonplatinum
compounds such as PLD, topotecan, or paclitaxel.4 Here, we
report substantial clinical activity of cisplatin-based combi-
nation chemotherapy in this difficult-to-treat patient group.
In our single-institution series of 34 patients with primary
‘‘platinum resistance,’’ median PFS and OS were 6.4 and
10.6 months, respectively, with 45% of patients achieving ra-
diologic responses by RECIST criteria.
Treatment with ECX was feasible and, despite the rel-
atively high rates of neutropenia and infection, treatment dis-
continuations for reasons other than disease progression were
infrequent. Cycle delays were uncommon, affecting 13% of
cycles, and 80% to 90% of patients received at least 90% of
the planned dose for each of the 3 drugs. The problems with
prolonged neutropenia seen with ECarboX15 seem to have
been significantly improved by resubstituting cisplatin for
carboplatin in the ECX regimen used in the current study. The
overall toxicity profile of the regimen is similar to the ECX
regimen used in gastroesophageal cancer, with the exception of
nausea and vomiting, which seem significantly more common
in the ovarian population (30%-40% vs G10%).18 The higher
rates seen in our study could be related to different disease
distribution, affecting the peritoneum, and patient demo-
graphics. Toxicity rates are similar to those seen with other
platinum-based combination regimens including dose-dense
regimens, although with less G3/4 neurotoxicity.
Our results are similar to those reported in multiple
single arm phase II studies for patients with platinum-resistant
diseasewith regimens such as cisplatin-gemcitabine,11 cisplatin-
etoposide,13 cisplatin-ifosfamide,19 dose-dense carboplatin
paclitaxel,20 oxaliplatin-5FU,12 or alternating PLD/gemcitabine
and cisplatin/cyclophosphamide.21 In these studies, RR ranged
from29% to 51%and PFS from4.9% to 8months.Most of these
studies reported lowerRR in patientswith PFIG 3months,11,13,19
a finding also seen in our seriesVpatientswith TTP1G 3months
had particularly poor outcomes with median PFS and OS of 1.8
and 3.2 months, respectively. Consistent with this, in multivariate
models, platinum-refractory status and short TTP1 were the
most significant predictors of short OS and PFS. However,
it should be noted that these observations may be confounded
by histology because 6 of the 8 platinum refractory statuses
were of clear cell histotype. Although the regression models
suggest that platinum-refractory status is a stronger predictor
of poor outcomes than clear cell histology, examination of a
larger data set is needed to increase confidence in this con-
clusion. In our evaluation, ECX showed considerable activity in
patients with TTP1 9 3 months: median PFS and OS were 7.9
and 14.7months, respectively, andORRwas 60% in this group.
The high response in this group may explain our interesting
observation that early response to ECX, compared with disease
stabilization, was associated with significantly prolonged OS,
contrary to previous reports in which outcomes in patients
achieving SD were similar to those achieving PR/CR.22
A strength of our series is that we restricted eligibility to
patients with primary platinum resistance only, whereas most
previously published studies have included a mix of patients
with primary and secondary (ie, developing after Q2 platinum
courses) resistance. Little is known at present about specific
differences in resistance pathways between patients with pri-
mary and secondary resistance; however, tumors with adverse
characteristics such as CCNE1 amplification and increased pro-
liferation seem to be enriched in the first group.23 Data from
our series support the notion that platinum-based combinations
can overcome primary platinum resistance in EOC. Limitations
of this study include incomplete information on potential
confounders such as performance status, residual disease
postsurgery, and response assessments. Retrospective collec-
tion of adverse event grading from the medical records may
either underestimate their frequency in our series, especially for
low-grade toxicities, or overestimate because causality may be
over attributed. Our OS results may have been affected by
variations in the availability of other treatments over the time
span of this series. Because there was no randomization, it
cannot be established that similar outcomes could not have been
achieved with nonYplatinum-based regimens; however, any
selection bias operating would equally apply to a prospective
single-arm study.
What is the way forward for platinum-based chemo-
therapy in platinum-resistant relapse? Evidence from a number
of studies now suggests that patients with primary platinum
resistance and TTP1 G 3 months seem to have very poor out-
comes and should be prioritized for entry into clinical trials of
FIGURE 2. PFS and OS according to TTP1.
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novel agents or best supportive care, as appropriate. Consid-
ering our results in the context of other studies of platinum-
based chemotherapy in patients with platinum-resistant relapse
and TTP1 9 3 months, it seems that outcomes with platinum-
based combinations are at least as good as those achieved with
the best nonYplatinum-containing regimens (weekly paclitaxel
plus bevacizumab or trebananib as per the AURELIA10 and
TRINOVA-124 studies, respectively). The response to platinum
seen in this and other studies challenges the dogma that the RRs
in this population are 10%,25 a figure derived in an era when
platinum resistance was defined by clinical progression. An
explanation for the discrepancy is that with modern surveillance
practice and earlier detection of relapse, this RR may more
closely reflect what would now be considered the platinum
refractory population.
Given the limited activity of single-agent capecitabine26
or 5FU27 in EOC, and the substantial additive benefit of PLD
to platinum in both in the first-line28 and relapse setting,29 it
is not clear whether capecitabine contributes to the activity
of the cisplatin-epirubicin backbone in ECX. It is tempting to
speculate that similar efficacy with less toxicity could be
achieved with the combination of a more tolerable platinum
and anthracycline such as carboplatin and PLD alone in the
93-month TTP1 group.
Furthermore, given the significant improvement in PFS
from the addition of bevacizumab30 or cediranib31 to platinum-
based chemotherapy in patients with platinum-sensitive re-
lapse, it will be interesting to study whether the same benefits
are seen from these agents when added to platinum-based
chemotherapy in platinum-resistant EOC. Therefore, a pro-
spective comparisonof a platinum-anthracycline chemotherapy
regimen against weekly paclitaxel (with or without an angio-
genesis inhibitor in both arms) in patients with primary plati-
num resistance and TTP1 9 3 months would be recommended.
That ours (RECIST ORR, 45%; median PFS, 6.4 months) and
others’ results with platinum-based chemotherapy without
an antiangiogenesis agent11Y13,19Y21 are very similar to those
achieved with the current standard of care of nonplatinum
chemotherapy plus bevacizumab in AURELIA (ORR, 31%;
median PFS, 6.7 months) in platinum-resistant patients pro-
vides support for such a study. Should that happen, biospecimen
collection will be extremely important in trying to define
molecular biomarkers of response to treatment to supplement
clinical ones such as TTP1.
CONCLUSIONS
We report significant activity with manageable toxicity
of second-line cisplatin-epirubicin-capecitabine chemothera-
py inEOCpatientswith primaryplatinum resistance and time to
progression greater than 3 months. Platinum-based chemo-
therapy remains an option for these patients and needs to be
prospectively compared with standard-of-care treatments in
this setting.
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